Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to Hold

Immatics (NASDAQ:IMTX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other research analysts also recently issued reports on IMTX. Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Immatics in a report on Thursday, December 4th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Immatics in a research note on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Guggenheim boosted their price objective on Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, Mizuho set a $25.00 target price on shares of Immatics in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.20.

Immatics Stock Down 2.3%

Shares of NASDAQ:IMTX opened at $10.06 on Friday. Immatics has a 12 month low of $3.30 and a 12 month high of $12.41. The firm has a market cap of $1.22 billion, a P/E ratio of -9.86 and a beta of 1.36. The company’s 50-day moving average price is $9.89 and its two-hundred day moving average price is $8.90.

Institutional Investors Weigh In On Immatics

Several large investors have recently bought and sold shares of IMTX. T. Rowe Price Investment Management Inc. boosted its position in shares of Immatics by 10.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after purchasing an additional 2,075,987 shares in the last quarter. Baker BROS. Advisors LP grew its position in shares of Immatics by 18.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock valued at $103,042,000 after purchasing an additional 1,925,193 shares during the period. RTW Investments LP increased its stake in Immatics by 29.7% during the 4th quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock worth $120,050,000 after purchasing an additional 2,617,737 shares in the last quarter. Perceptive Advisors LLC increased its stake in Immatics by 10.7% during the 4th quarter. Perceptive Advisors LLC now owns 10,383,456 shares of the company’s stock worth $109,026,000 after purchasing an additional 1,000,000 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in Immatics by 1.6% during the 3rd quarter. Vestal Point Capital LP now owns 6,350,000 shares of the company’s stock worth $54,102,000 after buying an additional 100,000 shares during the period. Institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.